A clinical trial at Temple University Hospital is investigating the effectiveness of a vibrating capsule in alleviating symptoms of chronic constipation. The non-drug therapy involves a tiny motorized capsule that vibrates to stimulate intestinal contractions and help move stool through the digestive tract efficiently.
Cardiothoracic surgeons are stepping back as vascular specialists play a larger role in managing patients with Type B aortic dissections. Advances in minimally invasive endovascular surgery have driven this shift.
Temple University School of Medicine has received a $100,000 Grand Challenges Explorations grant to develop a non-invasive maternal blood test that predicts abnormal fetal neurodevelopment. The project aims to identify biomarkers in maternal blood that can predict healthy fetal brain development and guide interventions.
Researchers at Temple University Health System found that patients with non-cardiac chest pain experienced improved pain tolerance and reduced symptoms when treated with dronabinol. The study suggests a potential new approach for treating this condition, which affects an estimated 200,000 Americans annually.
Researchers identify butorphanol's target areas in the brain responsible for relieving itch, shedding light on its effectiveness against histamine-mediated and nonhistaminergic types of itch. The study's findings suggest that opioid receptors play a crucial role in modulating itch transmission.
Temple University researchers discovered a promising new target for treating end-stage heart failure by blocking the vasopressin type 1A receptor, which interferes with the heart's ability to receive important signals. The finding could lead to more effective therapies and improve symptoms in patients with heart failure.
A recent study published in JAMA Dermatology found that nearly 36.9% of skin cancer lesions are accompanied by itching, while 28.2% involve pain. Non-melanoma skin cancers are more likely to be associated with itch or pain.
A recent Temple University Health System study compared the safety of two treatments for deep vein thrombosis (DVT): catheter-based clot removal and blood-thinning medication. The study found similar in-hospital mortality rates for both groups, but higher bleeding risks with the catheter procedure.
Researchers at Temple University have successfully eliminated the HIV virus from cultured human cells using a molecular tool that targets and deletes the viral genome. The approach has potential as both a treatment and prevention method for HIV, offering hope for a cure for AIDS.
Researchers at Temple University School of Medicine are working on three projects to investigate key molecular mechanisms in heart failure, aiming to develop new therapies. The projects focus on signaling pathways implicated in cardiac injury and repair, with the goal of having new treatments ready for patients.
A large multicenter clinical trial led by Dr. Gerard J. Criner found that statin drugs do not reduce the number and severity of flare-ups from chronic obstructive pulmonary disease (COPD). The study tested the hypothesis that statins may be beneficial in persons with COPD due to their anti-inflammatory effect.
Temple researchers have shown that identical or compatible blood types between donor and recipient do not affect rejection rates in double-lung transplants. The study confirms excellent post-transplant lung function and comparable mortality rates for compatible donors.
A team of surgeons, led by Dr. T. Sloane Guy, has successfully performed a robotic operation to reconstruct the tricuspid valve in patients with infective endocarditis. The procedure uses a bioscaffold material that allows new tissue to grow, offering a potential cure for this potentially fatal bacterial disease.
A new multilayer stent may revolutionize the treatment of aortic aneurysms in the US, offering improved outcomes and reduced need for surgical bypass grafts. The device has already shown promising results in European trials, with patients experiencing similar or better outcomes than those treated with traditional stents.
Scientists discovered how mitochondria handle excess calcium, a mechanism that can lead to vascular damage and various diseases. The study sheds light on ways to prevent cell injury by slowing down calcium uptake and protecting mitochondria.
Dr. Steven R. Houser, Director of the Cardiovascular Research Center at Temple University School of Medicine, has made significant contributions to cardiovascular research over nearly three decades. He received prestigious honors from the American Heart Association for his work on heart cell function and regenerative pathways to repair...
Researchers at Temple University have discovered that inhibiting a specific protein called TNNI3K can limit damage from heart attacks and protect the heart from further injury. The findings have significant potential for translation into human patients and could lead to the development of a new treatment using a TNNI3K inhibitor.
A study led by Temple University School of Medicine reveals that beta-blockers and nitrates may help the failing heart by blocking enzyme GRK2, which can trigger heart cell death. This finding suggests new drugs aimed at GRK2 could protect the heart from progressive disease.
Researchers found that cortical bone-derived stem cells (CBSCs) triggered the growth of new blood vessels and matured into heart muscle cells, improving survival and heart function in mice. The study challenges the general assumption that cardiac stem cells are the most capable of repairing damaged heart tissue.
Researchers aim to improve treatment and rehabilitation strategies for children with spinal cord injuries using diffusion tensor imaging (DTI). The study plans to enroll 100 children, including those with spinal cord injuries and healthy controls.
Researchers at Temple University School of Medicine found that synthetic anti-inflammatory substances related to marijuana's active ingredient can attenuate HIV replication in macrophages. This discovery could lead to new drug therapies for HIV/AIDS, leveraging the human immune system's natural defenses.
A team of scientists at Temple University School of Medicine has identified a key molecule, GRK2, in mitochondria that contributes to the death of heart cells. The researchers found that blocking this enzyme's activity can prevent its delivery to mitochondria and reduce pro-death signaling.
Researchers at Temple University School of Medicine have identified a biochemical step underlying heart failure that could aid the development of new drugs. GRK5 enzyme gains access to heart cells' nucleus via calcium and calmodulin, leading to hypertrophy and ultimately heart failure.
Researchers at Temple University Health System have identified a potential target for treating sepsis: the STIM1 protein. By blocking its activity, they halted a cascade of cellular events that lead to out-of-control inflammation and protected lungs from severe damage. The findings may lead to new treatment strategies against sepsis.
Researchers have found that the human papillomavirus 16 (HPV16) is present in the brains of individuals with a common form of childhood epilepsy. The discovery suggests that the virus may play a role in the development of the condition, and could lead to new therapeutic options related to HPV.
A retrospective analysis of over 36,000 patients with colon cancer found that those with early stage disease and diabetes or high blood pressure have a greater risk for cancer return and death compared to patients without these conditions. High lipid levels were also found to be protective against recurrence.
Researchers found that tyrosine kinase inhibitor-resistant leukemia stem cells accumulate DNA damage, potentially leading to disease relapse. Identifying this source of genomic instability may help develop new treatment strategies against CML and other resistant diseases.
Researchers block DNA repair pathway in leukemia stem cells by targeting protein RAD52, which is crucial for fixing genetic mistakes. This approach may lead to a new strategy to overcome drug resistance in cancer patients.
Researchers at Temple University and the University of Pennsylvania identified a key protein, MCUR1, that regulates calcium entry into mitochondria. This discovery may lead to new treatment opportunities for diseases involving excessive calcium in cells.
Researchers at Temple University have identified a mitochondrial 'gatekeeper' protein called MICU1 that regulates calcium influx into the cell's power source. This finding may lead to new therapeutic options for diseases such as cardiovascular disease, diabetes, and neurodegeneration.
The National Institutes of Health has awarded Temple University Hospital a $1 million grant to participate in the Neurological Emergencies Treatment Trials Network. The five-year study series aims to facilitate high-quality clinical trials for various emergency neurological disorders, including traumatic brain injuries and seizures.
Researchers found significant improvement in sensory avoiding behaviors and tactile sensitivity after therapy sessions for children with ADHD. The treatment helped children better attend to lessons in noisy classrooms and participate in family activities.
Researchers transplanted skeletal muscle cells directly into a damaged area of the heart in a Phase I trial to test their potential to repair and strengthen heart contractions. The goal is to improve cardiac function and determine cell survival.
Temple University Hospital has introduced the internal jaw distraction device DynaForm, which helps regrow destroyed bone and correct facial deformities. The device is less cumbersome than traditional methods and can be used as an alternative to painful extraction for severe tooth crowding.
A study at Temple University Health System investigates whether donor bone marrow can coax recipients' immune systems to coexist without rejection of the transplanted hearts. If successful, it could lead to longer survival and reduced need for re-transplantations.